Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Inhibition of reactive oxygen species limits expansion of chronic lymphocytic leukemia cells

Leukemia volume 31, pages 2273–2276 (2017)Cite this article

Subjects

A key physiological role of reactive oxygen species (ROS) in biological processes and diseases has gained more attention over the past years. ROS produced by cells of the immune system, for example, neutrophils, macrophages and B cells, consist primarily of hydrogen peroxide (H2O2), superoxide (O2−) and hydroxyl radicals (OH−) that facilitate cell processes such as homeostasis and antimicrobial responses.1

Several studies have indicated a relationship between ROS and chronic lymphocytic leukemia (CLL) cell survival.2, 3, 4 Upon crosslinking and activation of the B-cell receptor (BCR) on the surface of B cells, particularly in B2 B cells, NOX2 produces ROS that subsequently inhibits tyrosine phosphatases.5 This inhibition then promotes BCR signal amplification.5 Unlike B2 B cells, CD5+ B1a B cells, which are already detected during early fetal development and which reside primarily in the peritoneal cavity (PerC), are autoreactive and spontaneously secrete IgM.6 These B1a B cells show distinct characteristics compared with that of B2 B cells in response to BCR ligation.6

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Holmstrom KM, Finkel T . Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol 2014; 15: 411–421.

    Article  CAS  Google Scholar 

  2. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P . Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101: 4098–4104.

    Article  CAS  Google Scholar 

  3. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol 2012; 14: 276–286.

    Article  CAS  Google Scholar 

  4. Jitschin R, Hofmann AD, Bruns H, Giessl A, Bricks J, Berger J et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood 2014; 123: 2663–2672.

    Article  CAS  Google Scholar 

  5. Reth M . Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002; 3: 1129–1134.

    Article  CAS  Google Scholar 

  6. Rothstein TL . Cutting edge commentary: two B-1 or not to be one. J Immunol 2002; 168: 4257–4261.

    Article  CAS  Google Scholar 

  7. Hayakawa K, Formica AM, Colombo MJ, Ichikawa D, Shinton SA, Brill-Dashoff J et al. B cells generated by B-1 development can progress to chronic lymphocytic leukemia. Ann NY Acad Sci 2015; 1362: 250–255.

    Article  CAS  Google Scholar 

  8. Iacovelli S, Hug E, Bennardo S, Duehren-von Minden M, Gobessi S, Rinaldi A et al. Two types of BCR interactions are positively selected during leukemia development in the Emu-TCL1 transgenic mouse model of CLL. Blood 2015; 125: 1578–1588.

    Article  CAS  Google Scholar 

  9. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005; 174: 4389–4399.

    Article  CAS  Google Scholar 

  10. Yigit B, Halibozek PJ, Chen SS, O'Keeffe MS, Arnason J, Avigan D et al. A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells. Oncotarget 2016; 7: 26346–26360.

    Article  Google Scholar 

  11. Chen SS, Batliwalla F, Holodick NE, Yan XJ, Yancopoulos S, Croce CM et al. Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling. Proc Natl Acad Sci USA 2013; 110: E1500–E1507.

    Article  CAS  Google Scholar 

  12. Herman SE, Niemann CU, Farooqui M, Jones J, Mustafa RZ, Lipsky A et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia 2014; 28: 2188–2196.

    Article  CAS  Google Scholar 

  13. Raza MH, Siraj S, Arshad A, Waheed U, Aldakheel F, Alduraywish S et al. ROS-modulated therapeutic approaches in cancer treatment. J Cancer Res Clin Oncol 2017; e-pub ahead of print.

  14. Coutre SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 2015; 56: 2779–2786.

    Article  CAS  Google Scholar 

  15. Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010; 22: 1235–1238.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the NIH PO1-AI065687 to CT and NW.

Author contributions

BY designed and performed the experiments. S-SC, NC and NW provided input into the experiments. BY and CT wrote the manuscript. All authors read and approved the manuscript.

Author information

Authors and Affiliations

  1. Division of Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    B Yigit, N Wang & C Terhorst

  2. Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, NY, USA

    S-S Chen & N Chiorazzi

Authors
  1. B Yigit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S-S Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Chiorazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Terhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to B Yigit or C Terhorst.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yigit, B., Wang, N., Chen, SS. et al. Inhibition of reactive oxygen species limits expansion of chronic lymphocytic leukemia cells. Leukemia 31, 2273–2276 (2017). https://doi.org/10.1038/leu.2017.241

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2017.241

This article is cited by

Search

Advanced search

Quick links